ITRM vs. DRRX, EYEN, QLI, LPCN, VAXX, SLGL, FBRX, UBX, SNSE, and ACST
Should you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include DURECT (DRRX), Eyenovia (EYEN), Qilian International Holding Group (QLI), Lipocine (LPCN), Vaxxinity (VAXX), Sol-Gel Technologies (SLGL), Forte Biosciences (FBRX), Unity Biotechnology (UBX), Sensei Biotherapeutics (SNSE), and Acasti Pharma (ACST). These companies are all part of the "pharmaceutical preparations" industry.
DURECT (NASDAQ:DRRX) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking.
DURECT has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500.
DURECT received 180 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. Likewise, 65.83% of users gave DURECT an outperform vote while only 62.10% of users gave Iterum Therapeutics an outperform vote.
28.0% of DURECT shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 4.3% of DURECT shares are owned by insiders. Comparatively, 5.4% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
DURECT has higher revenue and earnings than Iterum Therapeutics. DURECT is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Iterum Therapeutics has a net margin of 0.00% compared to Iterum Therapeutics' net margin of -323.16%. Iterum Therapeutics' return on equity of -316.78% beat DURECT's return on equity.
DURECT presently has a consensus price target of $27.50, indicating a potential upside of 2,765.78%. Iterum Therapeutics has a consensus price target of $6.00, indicating a potential upside of 292.16%. Given Iterum Therapeutics' higher possible upside, equities analysts clearly believe DURECT is more favorable than Iterum Therapeutics.
In the previous week, Iterum Therapeutics had 2 more articles in the media than DURECT. MarketBeat recorded 5 mentions for Iterum Therapeutics and 3 mentions for DURECT. Iterum Therapeutics' average media sentiment score of 0.50 beat DURECT's score of 0.00 indicating that DURECT is being referred to more favorably in the media.
Summary
DURECT beats Iterum Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Iterum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iterum Therapeutics Competitors List
Related Companies and Tools
